type 2 diabetes glp 1 GLP-1 receptor agonists are increasingly used to treat and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read Glucagon-like peptide 1(GLP-1) receptor agonists

Interpreted alongside observational data and mechanistic evidence, these findings support tirzepatide as an effective therapy for cardiovascular risk reduction in patients with T2D and established ASCVD or high CV risk, with benefits at least comparable to GLP-1RAs

References: American Society of Health-System Pharmacists

The ultimate goal is consistent, effective dosing with minimal waste

Sign up No prick peptides

Bitter extracts are sometimes used to stimulate appetite

Cytotoxic T cells elevate in peripheral blood and bronchoalveolar lavage of PASC patients with severe airway dysfunction with persistent respiratory symptoms that last for 3 to 6 months 212